The reliance on non-human biological models has long been a bottleneck in the pharmaceutical pipeline, leading to costly failures when results from mice or monkeys fail to replicate in clinical settings. However, the recent unveiling of the Pakistan Genome Resource provides a massive leap forward
The scientific community has long searched for a way to reverse the cellular decay associated with chronic organ failure, yet recent breakthroughs suggest that a medication originally designed to repair cardiac tissue may hold the key to regenerating damaged kidneys. This innovative therapeutic
Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, focusing on the intersection of technology and patient-centric innovation. In this discussion, we explore the implications of the U.S. FDA’s recent acceptance of Gilead’s supplemental New Drug
The traditional reliance on non-selective systemic chemotherapy for treating advanced gynecological malignancies is rapidly fading as clinicians embrace the precision of antibody–drug conjugates. For decades, the standard approach to ovarian, cervical, and endometrial cancers involved cytotoxic
The historical paradigm where Western laboratories exclusively dictated the rhythm of pharmaceutical progress is rapidly disintegrating as China establishes itself as a primary source of high-value drug candidates. For many decades, the global healthcare sector followed a remarkably predictable
The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this
